Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

December 21, 2023

https://www.globenewswire.com/news-release/2023/12/21/2800335/0/en/Topline-Results-from-MYLOX-1-Trial-Demonstrate-Reduction-in-Fibrosis-of-the-Bone-Marrow-in-Patients-with-Myelofibrosis.html

BOSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ:GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced positive topline results from a Phase 2a trial of GB2064 for the treatment of myelofibrosis (the “MYLOX-1 trial”, NCT04679870).

Read more at globenewswire.com

Related news for (GLTO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.